356 related articles for article (PubMed ID: 22421986)
1. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.
Rachoń D
Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):205-9. PubMed ID: 22421986
[TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
3. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
4. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
[TBL] [Abstract][Full Text] [Related]
5. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
6. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
7. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma.
Dennedy MC; Smith D; O'Shea D; McKenna TJ
Eur J Endocrinol; 2010 Feb; 162(2):213-20. PubMed ID: 19906851
[TBL] [Abstract][Full Text] [Related]
8. Androgens in Cushing's Syndrome.
Arnaldi G; Martino M
Front Horm Res; 2019; 53():77-91. PubMed ID: 31499501
[TBL] [Abstract][Full Text] [Related]
9. Hyperandrogenism in adolescent girls.
Catteau-Jonard S; Cortet-Rudelli C; Richard-Proust C; Dewailly D
Endocr Dev; 2012; 22():181-193. PubMed ID: 22846529
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
11. Cushing's syndrome in women with polycystic ovaries and hyperandrogenism.
Fegan PG; Sandeman DD; Krone N; Bosman D; Wood PJ; Stewart PM; Hanley NA
Nat Clin Pract Endocrinol Metab; 2007 Nov; 3(11):778-83. PubMed ID: 17955019
[TBL] [Abstract][Full Text] [Related]
12. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism.
Unluhizarci K; Kaltsas G; Kelestimur F
Eur J Clin Invest; 2012 Jan; 42(1):86-94. PubMed ID: 21623779
[TBL] [Abstract][Full Text] [Related]
13. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
14. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
15. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
[TBL] [Abstract][Full Text] [Related]
16. Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome.
Putignano P; Bertolini M; Losa M; Cavagnini F
J Endocrinol Invest; 2003 Jun; 26(6):539-44. PubMed ID: 12952368
[TBL] [Abstract][Full Text] [Related]
17. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
Zhou R; Bird IM; Dumesic DA; Abbott DH
J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719
[TBL] [Abstract][Full Text] [Related]
18. Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions.
Tuten A; Sahmay S; Oncul M; Acikgoz AS; Imamoglu M; Gurleyen HC; Senturk ML
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():121-5. PubMed ID: 24768424
[TBL] [Abstract][Full Text] [Related]
19. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
20. The clinical evaluation of hirsutism.
Somani N; Harrison S; Bergfeld WF
Dermatol Ther; 2008; 21(5):376-91. PubMed ID: 18844715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
